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Background: Different assays, including the competitive Luminex immunoassay (cLIA),
secreted alkaline phosphatase neutralization assay (SEAP-NA), and virus-like particle-based
ELISA, are commonly used to measure antibody responses after human papillomavirus
(HPV) vaccination. Direct assay comparisons aid interpretation of immunogenicity data
evaluated by different assays.
Methods: We compared cLIA to SEAP-NA and ELISA among 51 HPV16/18-vaccinated
women enrolled in the Costa Rica Vaccine Trial. We tested replicate serum samples col-
lected at months 0, 1, and 12 by HPV16/18 cLIA, SEAP-NA, and ELISA. For a subset (N =10),
we further tested month 6, 24 and 36 samples. We calculated seroprevalence estimates
and Spearman rank correlation coefficients comparing cLIA to SEAP-NA and ELISA.
Results: After one vaccine dose, seroprevalence by SEAP-NA and ELISA was 100% (both
HPV16 and HPV18), and by cLIA was 96% (95% CI 87–100%) for HPV16 and 71% (95%
CI 56–83%) for HPV18. Seroprevalence was 100% by all assays after three doses. Corre-
lation between assays was high after one vaccine dose [cLIA/SEAP-NA ρ=0.91 (HPV16)
and ρ=0.86 (HPV18); cLIA/ELISA ρ=0.84 (HPV16) and ρ=0.74 (HPV18); all p<0.001] and
remained high through month 36. Ratios of mean antibody levels to seropositivity cutoffs
at month 36 were lower for cLIA than for SEAP-NA or ELISA, particularly for HPV18 (HPV18
ratio for cLIA 1.9, SEAP-NA 3.5, ELISA 3.4).
Conclusion:Though correlation between cLIA and SEAP-NA/ELISA is high and stable after
vaccination, the assays differ in scale and sensitivity, with notable differences after one vac-
cine dose and for HPV18. Our results demonstrate that comparisons of antibody responses
to HPV vaccination measured by different assays are approximate, and must consider
biological and technical differences between assays.
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INTRODUCTION
Two human papillomavirus (HPV) virus-like particle (VLP)
vaccines, the bivalent (HPV16/18) Cervarix® and quadrivalent
(HPV6/11/16/18) Gardasil®, are licensed for prevention of cer-
vical cancer and related lesions (1). Four-year efficacy of both
vaccines approaches 100% among HPV-naïve women for preven-
tion of high-grade lesions related to HPV types 16 and 18 (2, 3),
which together cause 70% of cervical cancers (4).
Neutralizing antibody responses are believed to be the pri-
mary mechanism of vaccine-induced protection (5), but different
type-specific assays are used to measure them. For Cervarix®, the
principal assay for measuring immunogenicity has been the VLP-
based ELISA, which measures neutralizing and non-neutralizing
antibodies of one immunoglobulin class (typically IgG). Neu-
tralizing responses to Cervarix® have been measured using the
secreted alkaline phosphatase neutralization assay (SEAP-NA),
which broadly and directly measures neutralization potential (6).
For Gardasil®, the proprietary competitive Luminex immunoassay
(cLIA) is primarily used, which measures neutralizing antibodies
that compete for binding to one VLP epitope (7).
Measured antibody responses are important, as they are used
as evidence of vaccine immunogenicity, but results vary by assay.
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When different vaccines are evaluated using different assays, vari-
ability in results may be due to assay differences or due to true
differences in immunogenicity (8). To facilitate interpretation of
measurements by different assays, direct comparisons of assays
have been published in both natural infection and vaccination con-
texts (9–12). A previous report by our group compared SEAP-NA
to ELISA after vaccination with Cervarix®, finding high correlation
between the two assays (10). Here, we extend these results by pre-
senting a detailed and longitudinal post-vaccination comparison
of cLIA to SEAP-NA and ELISA.
MATERIALS AND METHODS
We evaluated women selected from the HPV vaccine arm of the
Costa Rica Vaccine Trial (CVT) (13), in which participants were
vaccinated with Cervarix® at months 0, 1, and 6. For the present
study, we combined two groups of women sampled for previous
serological studies where HPV16/18 SEAP-NA and ELISA test-
ing were already performed (10, 14, 15). The first group included
50 randomly sampled women, and the second group included 12
women sampled with the requirement of no cervical infection with
HPV types 16, 18, 31, 45, or 58 at baseline (month 0). We further
tested replicate sera from these 62 women collected at months 0,
1, and 12 by HPV16/18 cLIA; for the smaller group, we addition-
ally tested samples from months 6, 24 and 36. We excluded four
women who received fewer than three vaccine doses and five for
whom any of the assays failed, and further excluded two women
with anomalous results in post-vaccination samples. One woman
was seronegative by all assays at month 12 despite a normal anti-
body response at other time points; we suspect this may reflect
a sample retrieval error. The second woman never seroconverted
by HPV16/18 cLIA after vaccination; this may indicate a technical
error but does not imply a vaccine failure as other assays showed
the expected antibody response. As results did not differ by group,
we conducted analyses among a combined analytical sample of 51
women, equal to 62 less 11 exclusions.
The SEAP-NA was performed at the HPV Immunology Lab-
oratory, SAIC-Frederick Inc., as described (6, 10), with results
reflecting the mean of at least duplicate testing (maximum of
15 runs) for each sample. Neutralization titers were calculated
by linear interpolation and were defined as the reciprocal of the
dilution that reduced SEAP activity by 50% compared to control
wells. We used the laboratory-determined seropositivity cutoff
of 10, which reflects our lowest dilution. The VLP-based ELISA
was performed at GSK Biologicals as described (16), with results
reflecting the mean of between 1 and 5 runs per sample, and
laboratory-determined seropositivity cutoffs of 8 EU/mL (ELISA
units per milliliter) (HPV16) and 7 EU/mL (HPV18) were used.
Data describing our ELISA (10) and SEAP-NA (10, 14, 15) results
have been published. The cLIA was performed at PPD Vaccines
and Biologicals as described (7), with use of standard curves to
convert mean fluorescence intensities to arbitrary milli-Merck
units per milliliter (mMU/mL). Laboratory-determined cutoffs of
20 mMU/mL (HPV16) and 24 mMU/mL (HPV18) are based on
an algorithm maximizing the distinction between “likely negative”
and “likely positive” samples (17).
We performed statistical analyses separately for HPV16 and
HPV18. Among the combined sample of 51 women, at months
0, 1, and 12, we compared cLIA to SEAP-NA and ELISA using
seroprevalence estimates, scatter plots, and Spearman rank corre-
lation coefficients. Among the subgroup of 10 women (12 less 2
exclusions), where we additionally had assay data at months 6, 24
and 36, we plotted individual antibody levels by each assay over
time. To quantify inter-assay correlation beyond month 12 (i.e.,
beyond time points available in the larger sample), we also calcu-
lated Spearman coefficients at month 36 among these 10 women.
For graphical presentation and calculation of correlation coeffi-
cients, values below assay lower limits of detection (LLODs) were
assigned a value of 1/2 (LLOD).
RESULTS
HPV16/18 antibody levels increased after vaccination as previ-
ously reported by SEAP-NA and ELISA (10, 14, 15) and by cLIA
(Figures 1 and 2). At 1 month after the first vaccine dose,all women
were HPV16 and HPV18 seropositive by SEAP-NA and ELISA
(Table 1). By cLIA, at month 1, 96% (95% CI 87–100%) and
71% (95% CI 56–83%) were seropositive for HPV16 and HPV18,
respectively. At month 12, all women were seropositive for both
HPV types by all three assays.
Prior to vaccination,when average antibody levels were very low
or below detection limits, correlation between cLIA and SEAP-NA
was moderate for HPV16 (ρ= 0.39, p= 0.004, Figure 1A) and
not present for HPV18 (ρ=−0.04, p= 0.774, Figure 1C). Results
were similar for cLIA and ELISA (ρ= 0.58, p< 0.001 for HPV16;
ρ=−0.07, p= 0.629 for HPV18, Figures 1B,D). Correlation was
high after one vaccine dose (i.e., at month 1), with Spearman
coefficients of 0.91 (HPV16) and 0.86 (HPV18) for cLIA and
SEAP-NA, and coefficients of 0.84 (HPV16) and 0.74 (HPV18)
for cLIA and ELISA (all p< 0.001). Correlation remained high
6 months after the third dose (i.e., at month 12), with Spearman
coefficients of 0.79 (HPV16) and 0.87 (HPV18) for cLIA and
SEAP-NA, and coefficients of 0.81 (HPV16) and 0.86 (HPV18)
for cLIA and ELISA (all p< 0.001). Discordant samples (i.e., sam-
ples seronegative by one assay but seropositive by the other) were
present only at months 0 and 1, and were seronegative by cLIA but
seropositive by either SEAP-NA or ELISA in all cases (Figure 1).
Using data at month 36 (N = 10), when plateau antibody levels are
expected, correlation coefficients were 0.89 (HPV16, p= 0.001)
and 0.83 (HPV18, p= 0.003) for cLIA and SEAP-NA, and 0.96
(HPV16, p< 0.001) and 0.92 (HPV18, p< 0.001) for cLIA and
ELISA (results not shown).
Antibody kinetics throughout and after vaccination were
largely similar across HPV types, assays, and the 10 women studied
(Figure 2), with increases in antibody levels throughout vac-
cination and a gradual decline after month 12. For HPV16/18
SEAP-NA and ELISA, levels were well above seropositivity cut-
offs beginning at month 1 (Figures 2C–F). For cLIA, particu-
larly for HPV18, levels were lower and closer to the seropos-
itivity cutoff (Figures 2A,B). To quantify this observation at
our final time point (month 36), we calculated the ratio of
the mean of log-antibody levels to the corresponding log-cutoff
(log-antibodymean: log-cutoff). For HPV16, these ratios were 2.4
for cLIA, 3.4 for SEAP-NA, and 3.6 for ELISA. For HPV18,
these ratios were 1.9 for cLIA, 3.5 for SEAP-NA, and 3.4 for
ELISA.
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FIGURE 1 | Antibody levels for HPV16 (A,B) and HPV18 (C,D), as
measured by cLIA vs. SEAP-NA (A,C) or cLIA vs. ELISA (B,D). Levels
were measured at months 0 (white markers), 1 (gray markers), and 12
(black markers) among 51 women in the Costa Rica Vaccine Trial who
received HPV vaccine doses at months 0, 1, and 6. Spearman rank
correlation coefficients between pairs of assays are displayed for each
time point, with asterisks denoting statistical significance (all p<0.005).
Dashed lines represent laboratory-determined seropositivity cutoffs. Note
differing scales for x - and y -axes, as assays use different scales for
measurement.
DISCUSSION
Different assays are used to monitor antibody responses following
HPV vaccination, with ELISA or SEAP-NA typically used for Cer-
varix® and cLIA for Gardasil®. To aid interpretation of immuno-
genicity data, we directly compared cLIA-measured responses to
ELISA- and SEAP-NA-measured responses after vaccination with
Cervarix®. Correlation between cLIA and both SEAP-NA and
ELISA was high beginning after one vaccine dose, with similar
antibody kinetics across assays. However, levels relative to seropos-
itivity cutoffs were lower by cLIA than by SEAP-NA or ELISA,
particularly for HPV18.
The cLIA, SEAP-NA, and ELISA are technically different assays
and measure different aspects of the antibody response (8). The
cLIA measures neutralizing antibodies of all immunoglobulin
classes that compete for binding to a specific VLP epitope (V5 for
HPV16, J4 for HPV18) by evaluating the strength of a fluorescent
signal produced by binding monoclonal antibodies (7). SEAP-
NA measures a reporter gene product which is expressed when
HPV pseudovirions infect susceptible cells, such that decreases in
expression reflect overall serum neutralizing potential (6), which
is assumed but not required to be antibody-mediated. ELISA mea-
sures one class of antibodies (typically IgG) that bind to a fixedVLP
antigen by measuring the activity of an enzyme conjugated to a
secondary antibody (16). These assays use different scales in terms
of measurement, and further differences exist in the structure and
production of the VLPs for each assay. The directed nature and
more stringent cutoff of cLIA affords it lower sensitivity than
SEAP-NA or ELISA (9); further, within the cLIA, the HPV18 J4 epi-
tope may be less immunodominant than the HPV16 V5 epitope.
In our study, the lower sensitivity of cLIA was likely responsible
for a number of discordant samples after vaccination. At month 1,
approximately 4% of samples were HPV16 seropositive by ELISA
and SEAP-NA but HPV16 seronegative by cLIA. The proportion
of discordant samples was larger (29%) for HPV18 at the same
visit, likely reflecting lower immunodominance of the HPV18 J4
epitope than the HPV16 V5 epitope. Relative to seropositivity cut-
offs, HPV18 antibody levels were substantially lower by cLIA than
by SEAP-NA or ELISA.
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FIGURE 2 | Individual patterns of antibody levels over time as measured
by cLIA (A,B), SEAP-NA (C,D), and ELISA (E,F) among 10 women in the
Costa Rica VaccineTrial who received HPV vaccine doses at months 0, 1,
and 6. Patterns are shown for HPV16 (A,C,E) and HPV18 (B,D,F). Bold solid
lines represent seropositivity cutoffs, and ratios at 36 months were calculated
as the mean of log-antibody levels to the log of the corresponding
seropositivity cutoff. HPV DNA negativity for types 16, 18, 31, 45, and 58 at
month 0 was required for selection.
Despite assay differences, we observed high and statistically sig-
nificant correlation between cLIA and both SEAP-NA and ELISA
beginning after one vaccine dose and extending to month 36,
with similar antibody kinetics across HPV types and assays. A
previous study, comparing cLIA to an in-house SEAP-NA, found
correlation coefficients of 0.67 (HPV16) and 0.91 (HPV18) 1
month after the third dose of Gardasil® (12). Another study
conducted among Gardasil® vaccinees compared cLIA to a total
IgG Luminex immunoassay, which is biologically similar to but
technically different from our ELISA (18). Results were similar
to our cLIA/ELISA comparison, with correlation coefficients at
months 7, 24, and 48 of 0.66, 0.90, and 0.91 for HPV16, and 0.84,
0.88, and 0.89 for HPV18. Our group previously reported high
correlation between SEAP-NA and ELISA for combined 1- and
12-month measurements, with coefficients of 0.91 (HPV16) and
0.85 (HPV18) (10).
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Table 1 | Seroprevalence by HPV type, assay, and visit among 51
women in the Costa Rica VaccineTrial.
HPV type Assay Seroprevalence and 95% confidence
intervala (%)
Month 0 Month 1 Month 12
HPV16 cLIA 4 (0–13) 96 (87–100) 100 (93–100)
SEAP-NA 33 (21–48) 100 (93–100) 100 (93–100)
ELISA 12 (4–24) 100 (93–100) 100 (93–100)
HPV18 cLIA 0 (0–7) 71 (56–83) 100 (93–100)
SEAP-NA 8 (2–19) 100 (93–100) 100 (93–100)
ELISA 20 (10–33) 100 (93–100) 100 (93–100)
Seropositivity was defined according to laboratory cutoffs (see Materials and
Methods). HPV vaccine doses were administered at months 0, 1, and 6.
aFor estimates where seroprevalence is 0 or 100%, a one-sided 97.5% confidence
interval is shown.
In conclusion, though agreement between assays is not high
prior to vaccination (9), among vaccinated women measurements
by cLIA, SEAP-NA, and ELISA correlate well and have similar
patterns over time. However, the assays differ in scale and sensitiv-
ity, with notable differences after one vaccine dose and for HPV18.
Comparisons of antibody responses to HPV vaccination measured
by different assays are therefore approximate, and must consider
biological and technical differences between assays.
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